Can a One-Two punch wake up and destroy hidden HIV?
NCT ID NCT07577986
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a combination therapy to target hidden HIV reservoirs. Twenty HIV-positive adults on stable antiretroviral therapy will receive chidamide (to reactivate dormant virus) followed by infusions of engineered NK cells designed to kill the reactivated cells. The main goal is to check safety, but researchers will also look for signs that the viral reservoir is shrinking.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chidamide combined with NKG2D CAR-NK cells
What this could lead to
If it works, this could point toward a functional cure for HIV, allowing patients to control the virus without lifelong medication.
What could go wrong
This is a very early, small trial (20 people) focused on safety. The 'shock and kill' approach has not yet been proven in humans, and there are risks like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV - HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
the first affiliated hospital of Zhejiang university school of medicine, Hangzhou, Zhejiang 310000
Hangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••